Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04532489 · ClinicalTrials.gov registry record · Early Phase 1
Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Group 1)
A Early Phase 1 study of Hypertension and Cholesterol, sponsored by Benjamin Viglianti.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT04532489: Recruiting Early Phase 1 study of Hypertension and Cholesterol, sponsored by Benjamin Viglianti.
NCT04532489 is a Early Phase 1 study of Hypertension and Cholesterol that is actively recruiting participants, run by Benjamin Viglianti. The registered enrollment target is 6 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04532489, a Early Phase 1 study of Hypertension and Cholesterol, is actively recruiting participants, sponsored by Benjamin Viglianti.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This exploratory, first-in-man, phase 0 study will evaluate the feasibility of using a sub-therapeutic dose of a fluorine-18 analogue of NP-59 (\[18F\]FNP-59) to image the adrenal gland in healthy normal subjects. The researchers believe that \[18F\]FNP-59 would greatly improve the imaging characteristics, by providing a PET imaging cholesterol analogue with significantly improved radiation dosimetry.
Primary Outcome
SUV will be reported. Both maximal and average SUVs will be calculated
Conditions Studied
Interventions
- DRUG FNP-59
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-01-18 |
| Est. Completion | 2026-12 |
| Phase | Early Phase 1 |
What NCT04532489 shows while recruiting
NCT04532489 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which FNP-59 is the first listed.
NCT04532489 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT04532489 about?
NCT04532489 is a clinical study titled "Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Group 1)". This exploratory, first-in-man, phase 0 study will evaluate the feasibility of using a sub-therapeutic dose of a fluorine-18 analogue of NP-59 (\[18F\]FNP-59) to image the adrenal gland in healthy normal subjects. The researchers believe that \[18F\]FNP-59 would greatly improve the imaging character...
What is the current status of trial NCT04532489?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2021-01-18. Estimated completion is 2026-12.
What conditions does trial NCT04532489 study?
This clinical trial studies the following conditions: Hypertension, Cholesterol, Radiotracer.
What interventions are being tested in trial NCT04532489?
The interventions under investigation include: FNP-59 (DRUG).
Who is sponsoring clinical trial NCT04532489?
This trial is sponsored by Benjamin Viglianti, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04532489 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04532489's enrollment target sits among peer trials
6 467th of 470 higher than 3 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension
RECRUITING · Early Phase 1
-
Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure
RECRUITING · Early Phase 1
-
Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)
RECRUITING · Early Phase 1
-
Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)
RECRUITING · Early Phase 1
-
Reversing Glucose and Lipid-mediated Vascular Dysfunction
RECRUITING · Early Phase 1
-
Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI